Searching the RRID Resource Information Network
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ben and Catherine Ivy Foundation Resource Report Resource Website 1+ mentions |
Ben and Catherine Ivy Foundation (RRID:SCR_006333) | Ivy Foundation | funding resource | Funds patient-focused research on gliomas to develop better diagnostics and treatments that lead to long-term survival and a high quality of life for patients with brain tumors. The goal is to decrease the suffering of patients with brain tumors. With an ultimate goal to cure brain cancer, their immediate goal is to improve diagnostics and treatment. They are dedicated to improving the lives of all patients with brain cancer by funding research that they hope will lead to the doubling of life expectancy of patients with brain cancer. Their goal is to do this within the next seven years. Since 2005 they''ve committed more than $50 million to research into brain tumors, with the expectation that this will lead to better diagnostics and therapies. They are dedicated to this search because funding leads to answers, and answers lead to hope. | glioma, research, brain, tumor, brain tumor, diagnostic, treatment | Brain cancer, Cancer | nlx_152043 | SCR_006333 | 2026-02-14 02:01:16 | 2 | |||||||||
|
BioGrid Australia Resource Report Resource Website 100+ mentions |
BioGrid Australia (RRID:SCR_006334) | BioGrid Australia | data analysis service, analysis service resource, data or information resource, production service resource, service resource, database | A federated data sharing platform and infrastructure that provides access to real-time clinical, imaging and biospecimen data across jurisdictions, institutions and diseases. The web-based platform provides a secure infrastructure that advances health research by linking privacy-protected and ethically approved data among a wide network of health collaborators. Access to de-identified health records data is granted to authorized researchers after an application process so patient privacy and intellectual property are protected. BioGrid Australia''s approved researchers are provided access to multiple institutional databases, via the BioGrid interface, preventing gaps in patient records and research analysis. This legal and ethical arrangement with participating collaborators allows BioGrid to connect data through a common platform where data governance and access is managed by a highly skilled team. Data governance, security and ethics are at the core of BioGrid''s federated data sharing platform that securely links patient level clinical, biospecimen, genetic and imaging data sets across multiple sites and diseases for the purpose of medical research. BioGrid''s infrastructure and data management strategies address the increasing need by authorized researchers to dynamically extract and analyze data from multiple sources whilst protecting patient privacy. BioGrid has the capability to link data with other datasets, produce tailored reports for auditing and reporting and provide statistical analysis tools to conduct more advanced research analysis. In the health sector, BioGrid is a trusted independent virtual real-time data repository. Government investment in BioGrid has facilitated a combination of technology, collaboration and ethics approval processes for data sharing that exist nowhere else in the world. | endocrinology, neuroscience, imaging, medicine, oncology, population, cancer, cystic fibrosis, diabetes, pet, mri, clinical, respiratory, health, epilepsy, neuropsychiatry, data sharing, FASEB list | Cancer, Diabetes, Epilepsy, Cystic fibrosis, Respiratory disease, Multiple Sclerosis, Stroke, Bone density | Closed; Authorized researchers only. | nlx_152036, r3d100012476 | https://doi.org/10.17616/R3921N | http://www.biogrid.org.au/wps/portal | SCR_006334 | BioGrid Australia Limited | 2026-02-14 02:01:08 | 294 | |||||
|
BC Cancer Foundation Resource Report Resource Website 1+ mentions |
BC Cancer Foundation (RRID:SCR_006428) | BC Cancer Foundation | institution | The fundraising partner of the BC Cancer Agency and the largest charitable funder of cancer research in this province. We enable donors to make contributions to leading-edge research that has a direct impact on improvements to cancer care for patients in British Columbia. By connecting philanthropy and research, we support the revolutionary advances that will help us achieve our vision of a world free from cancer. Our Cause: Supporting world-renowned cancer research in BC One in three British Columbians will be diagnosed with cancer in their lifetime. Because the BC Cancer Agency integrates research and treatment, the process from discovery to treatment is shorter, and researchers are asking questions focused on the needs of patients in BC. The BC Cancer Agency excels at translating exciting discoveries from the researcher''''s bench to the patient''''s bedside. This is the quickest and most effective way to impact cancer care, and it makes the Agency an international leader in cancer research. Our Donors: Leading the way in helping us advance our cause Our unique relationship with the BC Cancer Agency allows our donors to be part of research discoveries made right here in BC. We invite donors to become more connected to the BC Cancer Agency''''s world-leading research that is shaping the future of patient care. At the BC Cancer Foundation we are funding the areas of greatest priority and promise. We know, because we ask the scientists and clinicians at the BC Cancer Agency to identify the priorities and needs that will have the most significant and timely impact on cancer care and treatment. We then partner with our donors to raise the necessary funds in support of this life-saving work. Together we are funding and finding solutions that are having a direct impact on improving care for cancer patients in British Columbia. | british columbia, research | is related to: BC Cancer Agency | Cancer | nlx_151770, ISNI 0000 0001 0745 6244, grid.484001.9 | https://ror.org/03gqhbs95 | SCR_006428 | 2026-02-14 02:01:09 | 2 | |||||||
|
Cancer Genomics Hub Resource Report Resource Website 100+ mentions |
Cancer Genomics Hub (RRID:SCR_002657) | CGHub | data repository, storage service resource, data or information resource, service resource, database | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on March 17, 2022. A secure repository for storing, cataloging, and accessing cancer genome sequences, alignments, and mutation information from the Cancer Genome Atlas (TCGA) consortium and related projects. CGHub gives scientific researchers the statistical power of large cancer genome datasets to attack the molecular complexity of cancer. | genome, genome sequence, alignment, mutation | has parent organization: University of California at Santa Cruz; California; USA | Cancer | PMID:25267794 | THIS RESOURCE IS NO LONGER IN SERVICE. | r3d100011174, nlx_156095 | https://doi.org/10.17616/R3F919 | SCR_002657 | 2026-02-14 02:00:29 | 176 | |||||
|
Celgene Resource Report Resource Website 50+ mentions |
Celgene (RRID:SCR_002955) | CELG | commercial organization | An American global biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. The company's major products are Thalomid (thalidomide), which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL), as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma, and Revlimid (lenalidomide), for which the company has received FDA and EMA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Both Thalomid and Revlimid are sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS. Celgene also receives royalties from Novartis Pharma AG on sales of the entire Ritalin family of drugs, which are widely used to treat Attention Deficit Hyperactivity Disorder (ADHD). (Adapted from Wikipedia) There are numerous clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), glioblastoma, and ovarian, pancreatic and prostate cancer. | biopharmaceutical, drug, immune, inflammatory, clinical, medical, hematological, tumor, myeloma, myelodysplatic, syndrome, lymphocyte, leukemia, lymphoma, glioblastoma, ovarian, pancreatic, prostate, medicine, biotechnology | uses: FluoroFinder | Cancer, Immune disease, Inflammatory disease, Attention-Deficit Hyperactivity Disorder | THIS RESOURCE IS NO LONGER IN SERVICE | nif-0000-30309 | SCR_002955 | Celgene Corporation | 2026-02-14 02:00:28 | 52 | ||||||
|
Cancer Genome Anatomy Project Resource Report Resource Website 100+ mentions |
Cancer Genome Anatomy Project (RRID:SCR_003072) | CGAP | data or information resource, portal, topical portal | Project to determine the gene expression profiles of normal, precancer, and cancer cells, whose generated resources are available to the cancer community. Interconnected modules provide access to all CGAP data, bioinformatic analysis tools, and biological resources allowing the user to find in silico answers to biological questions in a fraction of the time it once took in the laboratory. * Genes * Tissues * Pathways * RNAi * Chromosomes * SAGE Genie * Tools | gene, gene expression, normal cell, precancer cell, cancer cell, cell, genome, anatomy, gene expression profile, tissue, pathway, rnai, chromosome, bio.tools |
is listed by: bio.tools is listed by: Debian has parent organization: National Cancer Institute is parent organization of: CGAP GO Browser |
Cancer, Normal, Precancer | NCI | Free, download Freely available | biotools:cgap, nif-0000-30468 | https://mitelmandatabase.isb-cgc.org/mb_search | SCR_003072 | Cancer Genome Anatomy Project (CGAP) | 2026-02-14 02:00:22 | 107 | ||||
|
Developmental Therapeutics Program Resource Report Resource Website 500+ mentions |
Developmental Therapeutics Program (RRID:SCR_003057) | DTP | portal, data or information resource, service resource, funding resource, topical portal | Portal for preclinical information and research materials, including web-accessible data and tools, NCI-60 Tumor Cell Line Screen, compounds in vials and plates, tumor cells, animals, and bulk drugs for investigational new drug (IND)-directed studies. DTP has been involved in the discovery or development of more than 70 percent of the anticancer therapeutics on the market today, and will continue helping the academic and private sectors to overcome various therapeutic development barriers, particularly through supporting high-risk projects and therapeutic development for rare cancers. Initially DTP made its drug discovery and development services and the results from the human tumor cell line assay publicly accessible to researchers worldwide. At first, the site offered in vitro human cell line data for a few thousand compounds and in vitro anti-HIV screening data for roughly 42,000 compounds. Today, visitors can find: * Downloadable in vitro human tumor cell line data for some 43,500 compounds and 15,000 natural product extracts * Results for 60,000 compounds evaluated in the yeast assay * In vivo animal model results for 30,000 compounds * 2-D and 3-D chemical structures for more than 200,000 compounds * Molecular target data, including characterizations for at least 1,200 targets, plus data from multiple cDNA microarray projects In addition to browsing DTP's databases and downloading data, researchers can request individual samples or sets of compounds on 96-well plates for research, or they can submit their own compounds for consideration for screening via DTP's online submission form. Once a compound is submitted for screening, researchers can follow its progress and retrieve data using a secure web interface. The NCI has collected information on almost half a million chemical structures in the past 50 years. DTP has made this information accessible and useful for investigators through its 3-D database, a collection of three-dimensional structures for more than 200,000 drugs. Investigators use the 3-D database to screen compounds for anticancer therapeutic activity. Also available on DTP's website are 127,000 connection tables for anticancer agents. A connection table is a convenient way of depicting molecular structures without relying on drawn chemical structures. As unique lists of atoms and their connections, the connection tables can be indexed and stored in computer databases where they can be used for patent searches, toxicology studies, and precursor searching, for example., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025. | cell line, drug discovery, drug development, drug, treatment, therapy, biopharmaceutical, bortezomib, paclitaxel, romidepsin, eribulin, sipuleucel-t, anticancer therapeutic, compound, natural product extract, animal model, in vivo, in vitro, chemical structure, chemical, structure, anti-hiv, anticancer, molecular structure, database, chemotherapeutic agent, testing, drug synthesis, chemistry, grant, contract, information technology, molecular pharmacology, natural product, pharmaceutical, screening technology, toxicology, pharmacology, screening, FASEB list |
is used by: NIF Data Federation is related to: Integrated Cell Lines has parent organization: National Cancer Institute |
Cancer, Tumor | NCI | THIS RESOURCE IS NO LONGER IN SERVICE | nif-0000-30447 | https://medschool.cuanschutz.edu/colorado-cancer-center/research/research-programs/developmental-therapeutics | SCR_003057 | Developmental Therapeutics Program NCI/NIH | 2026-02-14 02:00:29 | 562 | ||||
|
Dana-Farber Cancer Institute Resource Report Resource Website 1+ mentions |
Dana-Farber Cancer Institute (RRID:SCR_003040) | DFCI | institution |
Cancer institute that provides expert, compassionate care to children and adults with cancer while advancing the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases. As an affiliate of Harvard Medical School and a Comprehensive Cancer Center designated by the National Cancer Institute, the Institute also provides training for new generations of physicians and scientists, designs programs that promote public health particularly among high-risk and underserved populations, and disseminates innovative patient therapies and scientific discoveries to their target community across the United States and throughout the world. |
child, adult human, pediatric, young human |
has parent organization: Harvard Medical School; Massachusetts; USA is parent organization of: Spotfinder is parent organization of: TM4 Microarray Software Suite - TIGR MultiExperiment Viewer is parent organization of: Gene Index Project is parent organization of: CistromeMap is parent organization of: BINOCh is parent organization of: Dana Farber Tissue Bank is parent organization of: CistromeFinder is parent organization of: TM4 is parent organization of: WorfDB is parent organization of: Predictive Networks is parent organization of: RamiGO is parent organization of: DFCI Animal Resources Facility is parent organization of: DFCI Biohazard Containment Core Facility is parent organization of: DFCI Biospecimen Repository Core Facility is parent organization of: DFCI Blais Proteomics Center is parent organization of: DFCI Clinical Research Laboratory is parent organization of: DFCI Survey and Data Management Core is parent organization of: DFCI Flow Cytometry Core Facility is parent organization of: DFCI Medical Arts Core Facility is parent organization of: DFCI Microarray Core Facility is parent organization of: Dana-Farber Cancer Institute Molecular Biology Core Facility is parent organization of: DFCI RNA Interference Screening Facility is parent organization of: DFCI Shannon McCormack Advanced Molecular Diagnostics Laboratory is parent organization of: MAnorm is parent organization of: NPS is parent organization of: DFCI Confocal and Light Microscopy Core Facility is parent organization of: DFCI Monoclonal Antibody Core Facility is parent organization of: Dana-Farber Cancer Institute Labs and Facilities is parent organization of: DFCI Center for Cancer Computational Biology is parent organization of: GeneSigDB is parent organization of: MACS is parent organization of: DGAP |
Cancer | NCI ; Jimmy Fund |
Free, Freely available | Crossref funder ID: 100007886, grid.65499.37, Wikidata: Q1159198, ISNI: 0000 0001 2106 9910, nif-0000-30432 | https://ror.org/02jzgtq86 | SCR_003040 | Dana Farber Cancer Institute, Dana-Farber | 2026-02-14 02:00:37 | 6 | ||||
|
Janssen Research and Development Resource Report Resource Website 1+ mentions |
Janssen Research and Development (RRID:SCR_003904) | Janssen R&D | commercial organization | Pharmaceutical company with a mission to discover and develop innovative medicines that ease patients'' suffering, and solve the most important unmet medical needs of our time. As one of the Janssen Pharmaceutical Companies, their strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. They leverage their world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas: cardiovascular and metabolism, immunology, infectious diseases and vaccines, neuroscience, and oncology. | pharmaceutical, oncology, immunology, neuroscience, vaccine, medical |
is related to: Investigator Databank is related to: eTRIKS is related to: Predict-TB is related to: OncoTrack is related to: European Lead Factory is related to: EU-AIMS is related to: GetReal is related to: Kinetics for Drug Discovery is related to: MIP-DILI is related to: NEWMEDS is related to: ORBITO is related to: PharmaCog is related to: PREDECT is related to: Structural Genomics Consortium is related to: Open PHACTS is related to: EMIF is parent organization of: Investigator Databank |
Infectious disease, Cardiovascular disease, Metabolic disease, Immunological disorder, Cancer | nlx_158241 | SCR_003904 | Janssen Research & Development LLC, Janssen Research & Development | 2026-02-14 02:00:33 | 2 | |||||||
|
Althia Resource Report Resource Website |
Althia (RRID:SCR_003918) | Althia | commercial organization | A biomedical company in Spain focused on the development of new tools for diagnosis and personalized treatment of oncological diseases and precancerous. It has three areas of activity in permanent innovation: Assistance in Diagnosis / Prognosis in solid and hematological tumors, Translational Research covering the gap between basic and clinical research and advanced radiotherapy treatments based image-guided single dose (SD-IGRT). Their objectives are: * Provide an integrated tissue and tumor molecular phenotype analysis using the most advanced technologies in diagnosis, to guide the most appropriate treatment for each patient. * Discover and validate molecular patterns by molecular systems and platforms including pathology, to generate predictive algorithms through computational biology, evolution and determining the response of patients with a particular tumor profile. Althia has laboratories equipped with the most advanced equipment and technologies in Barcelona and Granada Genyo Center, with offices in Madrid. | oncology, diagnosis, prognosis, solid tumor, hematological tumor, translational, radiation, phenotype, analysis, pathology, hematology, hereditary | is related to: PRECISESADS | Cancer, Tumor, Solid tumor, Hematological tumor, Precancer | nlx_158279 | SCR_003918 | Althia Health Ltd., Althia Health, Advanced Laboratories of Translational Health, SL, S.L. | 2026-02-14 02:00:38 | 0 | |||||||
|
NYU Data Catalog Resource Report Resource Website |
NYU Data Catalog (RRID:SCR_004012) | NYU Data Catalog | data or information resource, database, catalog | A searchable data catalog that facilitates researchers'' access to large datasets available either publicly or through institutional or individual licensing. Dataset records include information about the content of the dataset, how to access the dataset, and local experts within NYULMC and NYU to assist in the use of these datasets. The data catalog will expand to include internally generated datasets from NYULMC and NYU in the near future. Use the contact form if you are interested in submitting a dataset to the data catalog. | data set, health, population, health care | Cancer, Chronic disease | The community can contribute to this resource | nlx_158439 | SCR_004012 | NYU Health Sciences Library Data Catalog | 2026-02-14 02:00:55 | 0 | |||||||
|
Experimental Pharmacology and Oncology Berlin-Buch Resource Report Resource Website 1+ mentions |
Experimental Pharmacology and Oncology Berlin-Buch (RRID:SCR_003954) | EPO | commercial organization | A small and medium-sized enterprise (SME) that has expertise in preclinical pharmacology, pharmacokinetics, and toxicology for the characterization of novel anticancer therapeutics and predictive biomarkers like: cytostatics, biologicals (peptides, antibodies), (anti)-hormones, immunomodulators (cytokines), and gene therapeutics. EPO has modern laboratories licensed for animal experiments and gene technology (S2) and a broad panel of murine and human tumor models growing in immunocompetent (SPF-quality, syngeneic strains) or immunodeficient mice (nude, SCID, NOD/SCID). EPO has established imaging technologies to monitor in vivo tumor growth. | tumor model, pharmaceutical, oncology, in vitro, in vivo, antitumor, preclinical, pharmacology, pharmacokinetics, toxicology, anticancer, therapeutic, biomarker, imaging, testing, validation, target | is related to: OncoTrack | Tumor, Cancer | nlx_158355 | SCR_003954 | EPO - Experimental Pharmacology & Oncology GmbH, Experimental Pharmacology & Oncology GmbH, Experimental Pharmacology & Oncology Berlin-Buch, Experimental Pharmacology & Oncology Berlin-Buch GmbH, EPO Berlin-Buch GmbH, EPO-GmbH | 2026-02-14 02:00:53 | 2 | |||||||
|
Alacris Theranostics Resource Report Resource Website |
Alacris Theranostics (RRID:SCR_003953) | Alacris | commercial organization | Commercial organization that uses next generation sequencing technologies coupled with computational modeling of tumor and somatic tissues in order to identify individualized therapies for cancer patients. The company also uses these technologies to help pharmaceutical partners stratify patients for their clinical trials. Alacris has an exclusive worldwide commercial license for the computational modeling of tumors and somatic tissues using proprietary computational systems modeling technologies ModCell developed at the Max Planck Institute for Molecular Genetics (MPI-MG) in Berlin coupled with next generation sequencing and genotyping technology developed at Harvard Medical School in Boston. The company also is building up the first next generation sequencing center in Europe for clinical operations. | next generation sequencing, computational modeling, clinical trial, somatic tissue, genotyping, genomics, oncogenomics, diagnostics, therapy, disease model, drug, personalized medicine, biomarker, drug development, tumor model, analysis, oncology | is related to: OncoTrack | Tumor, Cancer | nlx_158354, grid.473915.d | https://ror.org/04a0gnr15 | SCR_003953 | Alacris Theranostics GmbH | 2026-02-14 02:00:34 | 0 | ||||||
|
Big Ten Cancer Research Consortium Resource Report Resource Website |
Big Ten Cancer Research Consortium (RRID:SCR_004025) | BTCRC | data or information resource, organization portal, portal, consortium | A consortium that aims to transform cancer research through collaborative oncology trials that leverage the scientific and clinical expertise of the Big Ten universities. The goal is to align the conduct of cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise. The clinical trials that will be developed will be linked to molecular diagnostics, enabling researchers to understand what drives the cancers to grow and what might be done to stop them from growing. The consortium also leverages geographical locations and existing relationships among the cancer centers. One of the consortium's goals is to harmonize contracts and scientific review processes to expedite clinical trials. The consortium will only focus on phase 0 to II trials because larger trials - even a randomized phase II trial - are difficult to conduct at a single cancer center. | oncology, drug development, basic research, clinical trial, clinical, genitourinary, gastrointestinal, thoracic, breast, nanotechnology, virus, triple-negative cell |
is affiliated with: Penn State Milton S. Hershey Medical Center; Pennsylvania; USA is affiliated with: University of Wisconsin-Madison; Wisconsin; USA is affiliated with: Rutgers University; New Jersey; USA is affiliated with: Northwestern University; Illinois; USA is affiliated with: University of Nebraska; Nebraska; USA is affiliated with: University of Minnesota Twin Cities; Minnesota; USA is affiliated with: Michigan State University; Michigan; USA is affiliated with: University of Michigan; Ann Arbor; USA is affiliated with: University of Iowa; Iowa; USA is affiliated with: Indiana University; Indiana; USA is affiliated with: University of Illinois College of Medicine; Illinois; USA has parent organization: Hoosier Cancer Research Network |
Cancer | Public | nlx_158452 | SCR_004025 | Big Ten CRC | 2026-02-14 02:00:39 | 0 | ||||||
|
Hoosier Cancer Research Network Resource Report Resource Website |
Hoosier Cancer Research Network (RRID:SCR_004026) | HCRN | nonprofit organization | An independent nonprofit cancer research organization that provides full-service clinical trial management and support, from conception and study design through project completion and publication. Established to explore and develop leading edge cancer treatments across the United States and internationally, their clinical trials, developed in collaboration with academic and community oncologists, are conducted within a member network of more than 130 clinical research sites. Their vision and mission is to form unparalleled relationships between academic, community, pharmaceutical, and biotech partners with the goal of advancing cancer research, education, and patient advocacy. There are no costs to become a member. | oncology, clinical trial, clinical | is parent organization of: Big Ten Cancer Research Consortium | Cancer | nlx_158453, Wikidata: Q30287333, grid.428706.f | https://ror.org/02mtpb511 | SCR_004026 | Hoosier Oncology Group | 2026-02-14 02:00:55 | 0 | ||||||
|
DanStem Resource Report Resource Website 1+ mentions |
DanStem (RRID:SCR_004021) | DanStem | data or information resource, portal, topical portal | Center consisting of 9 research groups who all address basic questions in stem cell and developmental biology with the overall aim of developing new stem cell-based therapeutic approaches for diabetes and cancer. DanStem comprises two sections: * The Novo Nordisk Foundation Section for Basic Stem Cell Biology (BasicStem) * The Section for Strategic Translational Stem Cell Research and Therapy (TransStem) DanStem was established as a result of a series of international recruitments coupled with internationally recognized research groups focused on insulin producing beta cells and cancer research already located at the University of Copenhagen. They all have well-established, international collaborations and actively participate in several international scientific consortia. DanStem is also active in training undergraduates, PhD students and postdocs. | stem cell, beta cell development, beta cell, insulin |
is related to: Beta Cell Biology Consortium has parent organization: University of Copenhagen; Copenhagen; Denmark |
Diabetes, Cancer | Novo Nordisk Foundation ; Danish Council for Strategic Research |
nlx_158446 | SCR_004021 | The Danish Stem Cell Center, Danish Stem Cell Center, DanStem - The Center for Stem Cell Research, Danish Center for Stem Cell Research | 2026-02-14 02:00:39 | 4 | ||||||
|
BC Cancer Agency Resource Report Resource Website 1+ mentions |
BC Cancer Agency (RRID:SCR_004201) | BCCA | institution | A portal that provides a province-wide, population-based cancer control program for the residents of British Columbia and the Yukon. The BC Cancer Agency''s mandate covers the spectrum of cancer care, from prevention and screening, to diagnosis, treatment, and through to rehabilitation. The BC Cancer Agency''s mandate is driven by a three-fold mission: 1. To reduce the incidence of cancer; 2. To reduce the mortality rate of people with cancer; 3. To improve the quality of life of people living with cancer. This mission drives everything we do, including providing screening, diagnosis and care, setting treatment standards, and conducting research into causes of, and cures for, cancer. The BC Cancer Agency operates five regional cancer centers, providing assessment and diagnostic services, chemotherapy, radiation therapy, and supportive care. Each of the BC Cancer Agency''s centers delivers cancer treatment based on provincial standards and guidelines established by the Agency. We work in partnership with communities to provide a network of chemotherapy clinics so patients can receive care closer to home. Research is an essential part of the BC Cancer Agency''s mission to not only find the causes of cancer, but to find better treatments for prolonged life and better quality of life. With direct links between the BC Cancer Agency''s physicians and researchers at our five centers, the Deeley Research Centre (located in Victoria) and the BC Cancer Agency''s Research Centre (located in Vancouver), we can quickly translate new discoveries into clinical applications. The BC Cancer Agency''s Research Centre includes eight specialty laboratories including the Genome Sciences Centre, and the Terry Fox Laboratory. The BC Cancer Foundation raises funds for cancer research and enhancements to care at the BC Cancer Agency. |
is related to: BC Cancer Foundation is parent organization of: cisRED: cis-regulatory element is parent organization of: British Columbia Gynaecologic Tissue Bank is parent organization of: British Columbia Tumour Tissue Repository is parent organization of: Spark is parent organization of: ALEA is parent organization of: APOLLOH is parent organization of: British Columbia Breast Cancer Tumour Bank is parent organization of: JointSNVMix is parent organization of: mutationSeq is parent organization of: Mouse Gene Expression at the BC Cancer Agency is parent organization of: C. elegans Resources is parent organization of: BCCA Cancer Drug Manual is parent organization of: flowCL is parent organization of: flowBin |
Cancer | BC Cancer Foundation | ISNI: 0000 0001 0702 3000, Wikidata: Q4835275, grid.248762.d, nlx_143635, Crossref funder ID: 501100005614 | https://ror.org/03sfybe47 | SCR_004201 | British Columbia Cancer Agency | 2026-02-14 02:00:57 | 3 | ||||||
|
CDP Resource Report Resource Website 10+ mentions |
CDP (RRID:SCR_004236) | CDP | data or information resource, funding resource, portal, topical portal | National program to improve the diagnosis and assessment of cancer by moving scientific knowledge into clinical practice by coordinating and funding resources and research for the development of innovative in vitro diagnostics, novel diagnostic technologies and appropriate human specimens. The Cancer Diagnosis Program is divided into four branches: Biorepository and Biospecimen Research Branch (BBRB), Diagnostic Biomarkers and Technology Branch (DBTB), Diagnostics Evaluation Branch (DEB), and the Pathology Investigation and Resources Branch (PIRB). | cancer research, cancer funding, cancer research funding |
is listed by: OMICtools has parent organization: DCTD |
Cancer | NCI | Available to cancer researchers | OMICS_01536 | SCR_004236 | Cancer Diagnosis Program | 2026-02-14 02:00:42 | 19 | |||||
|
deCODE genetics Resource Report Resource Website 50+ mentions |
deCODE genetics (RRID:SCR_003334) | deCODE | commercial organization | A biopharmaceutical company applying its discoveries in human genetics to develop drugs and diagnostics for common diseases. They specialize in gene discovery - their population approach and resources have enabled them to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer. The company's genotyping capacity is now one of the highest in the world. They have a large population-based biobank containing whole blood and DNA samples with extensive relevant phenotypic information from around 120.000 Icelanders. In the company's work in more than 50 disease projects, their statistical and informatics departments have established themselves in data processing and analysis. deCODE genetics is widely recognized as a center of excellence in genetic research. | biopharmaceutical, genetics, drug, diagnostic, genotyping, phenotype, data processing, analysis, genetic variant, risk factor, genome, blood, dna, biobank, single nucleotide polymorphism |
is related to: EU-AIMS is related to: NEWMEDS |
Schizophrenia, Cardiovascular disease, Cancer, Type 2 diabetes, Atrial fibrillation, Heart attack | Free, Freely available | nif-0000-31959, ISNI: 0000 0004 0618 6889, grid.421812.c, Wikidata: Q493712 | https://ror.org/04dzdm737 | SCR_003334 | Islensk Erfdagreining EHF, Islensk Erfdagreining | 2026-02-14 02:00:46 | 57 | |||||
|
NCI Thesaurus Resource Report Resource Website 1+ mentions |
NCI Thesaurus (RRID:SCR_003563) | NCIt | data or information resource, ontology, controlled vocabulary | A reference terminology and core biomedical ontology for NCI that covers approximately 100,000 key biomedical concepts with terms, codes, definitions, and more than 200,000 inter-concept relationships. It is the reference terminology for NCI, NCI Metathesaurus and NCI informatics infrastructure covering vocabulary for clinical care, translational and basic research, and public information and administrative activities. It includes broad coverage of the cancer domain, including cancer related diseases, findings and abnormalities; anatomy; agents, drugs and chemicals; genes and gene products and so on. In certain areas, like cancer diseases and combination chemotherapies, it provides the most granular and consistent terminology available. It combines terminology from numerous cancer research related domains, and provides a way to integrate or link these kinds of information together through semantic relationships. NCIt features: * Stable, unique codes for biomedical concepts; * Preferred terms, synonyms, definitions, research codes, external source codes, and other information; * Links to NCI Metathesaurus and other information sources; * Over 200,000 cross-links between concepts, providing formal logic-based definition of many concepts; * Extensive content integrated from NCI and other partners, much available as separate NCIt subsets * Updated frequently by a team of subject matter experts. NCIt is a widely recognized standard for biomedical coding and reference, used by a broad variety of public and private partners both nationally and internationally including the Clinical Data Interchange Standards Consortium Terminology (CDISC), the U.S. Food and Drug Administration (FDA), the Federal Medication Terminologies (FMT), and the National Council for Prescription Drug Programs (NCPDP). | thesaurus, clinical, treatment, prevention, biomedical, owl, health, drug, chemotherapy |
is listed by: OBO is listed by: BioPortal is related to: NCI Metathesaurus is related to: OnEx - Ontology Evolution Explorer has parent organization: National Cancer Institute |
Cancer | See license, http://evs.nci.nih.gov/ftp1/NCI_Thesaurus/NCI_THESAURUS_license.txt | nlx_157698 | ftp://ftp1.nci.nih.gov/pub/cacore/EVS/ https://cabig.nci.nih.gov/concepts/EVS/ https://wiki.nci.nih.gov/display/EVS/NCI+Thesaurus+%28NCIt%29 http://nciterms.nci.nih.gov http://purl.bioontology.org/ontology/NCIT |
http://ncicb.nci.nih.gov/core/EVS | SCR_003563 | ncithesaurus | 2026-02-14 02:00:52 | 9 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the FDI Lab - SciCrunch.org Resources search. From here you can search through a compilation of resources used by FDI Lab - SciCrunch.org and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that FDI Lab - SciCrunch.org has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on FDI Lab - SciCrunch.org then you can log in from here to get additional features in FDI Lab - SciCrunch.org such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into FDI Lab - SciCrunch.org you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
The SciCrunch Infrastructure was developed as a cooperative data platform to be used by diverse communities in making data more FAIR.
scicrunch.org
